

PROJECT

Asthma - Study

Continued from Page

Sensitization BALB/c mice. exp1.

BALB/c From Jackson Laboratories.

| BALB/c | DOB | Weight(g) | Route of administration | Dose of sensitization | Alum | Systimic time | Systimic time |
|--------|----------|-----------|-------------------------|-----------------------|------|---------------|---------------|
| 386 | 11/26/01 | 23.8 | i.p. | 20ug OVA | 2mg | 2/18/02(day1) | 3/4/02(day14) |
| 387 | 11/26/01 | 24.4 | i.p. | 20ug OVA | 2mg | 2/18/02(day1) | 3/4/02(day14) |
| 388 | 11/26/01 | 25 | i.p. | 20ug OVA | 2mg | 2/18/02(day1) | 3/4/02(day14) |
| 389 | 11/26/01 | 27.8 | i.p. | 20ug OVA | 2mg | 2/18/02(day1) | 3/4/02(day14) |
| 390 | 11/26/01 | 24.8 | i.p. | 20ug OVA | 2mg | 2/18/02(day1) | 3/4/02(day14) |
| 391 | 11/26/01 | 22.7 | i.p. | 20ug OVA | 2mg | 2/18/02(day1) | 3/4/02(day14) |
| 392 | 11/26/01 | 24.1 | i.p. | 20ug OVA | 2mg | 2/18/02(day1) | 3/4/02(day14) |
| 393 | 11/26/01 | 22.7 | i.p. | 20ug OVA | 2mg | 2/18/02(day1) | 3/4/02(day14) |
| 394 | 11/26/01 | 24.8 | i.p. | 20ug OVA | 2mg | 2/18/02(day1) | 3/4/02(day14) |
| 395* | 11/26/01 | 26.4 | i.p. | 20ug OVA | 2mg | 2/18/02(day1) | 3/4/02(day14) |
| 396 | 11/26/01 | 25.8 | i.p. | 20ug OVA | 2mg | 2/18/02(day1) | 3/4/02(day14) |
| 397 | 11/26/01 | 23.3 | i.p. | 20ug OVA | 2mg | 2/18/02(day1) | 3/4/02(day14) |
| 398C | 11/26/01 | 22.4 | i.p. | PBS | 2mg | 2/18/02(day1) | 3/4/02(day14) |
| 399C | 11/26/01 | 26.1 | i.p. | PBS | 2mg | 2/18/02(day1) | 3/4/02(day14) |
| 400C | 11/26/01 | 26.4 | i.p. | PBS | 2mg | 2/18/02(day1) | 3/4/02(day14) |

| Airway challenge dose | Airway challenge time | Airway challenge time | Airway challenge time |
|-----------------------|-----------------------|-----------------------|-----------------------|
| 1% OVA 10min | 3/18/02(day28) | 3/19/02(day29) | 3/20/02(day30) |
| 1% OVA 10min | 3/18/02(day28) | 3/19/02(day29) | 3/20/02(day30) |
| 1% OVA 10min | 3/19/02(day28) | 3/20/02(day29) | 3/21/02(day30) |
| 1% OVA 10min | 3/18/02(day28) | 3/19/02(day29) | 3/20/02(day30) |
| 1% OVA 10min | 3/18/02(day28) | 3/19/02(day29) | 3/20/02(day30) |
| 1% OVA 10min | 3/19/02(day28) | 3/20/02(day29) | 3/21/02(day30) |
| 1% OVA 10min | 3/18/02(day28) | 3/19/02(day29) | 3/20/02(day30) |
| 1% OVA 10min | 3/19/02(day28) | 3/20/02(day29) | 3/21/02(day30) |
| 1% OVA 10min | 3/19/02(day28) | 3/20/02(day29) | 3/21/02(day30) |
| 1% OVA 10min | 3/18/02(day28) | 3/19/02(day29) | 3/20/02(day30) |
| 1% OVA 10min | 3/19/02(day28) | 3/20/02(day29) | 3/21/02(day30) |
| 1% OVA 10min | 3/19/02(day28) | 3/20/02(day29) | 3/21/02(day30) |
| PBS 10min | 3/18/02(day28) | 3/19/02(day29) | 3/20/02(day30) |
| PBS 10min | 3/19/02(day28) | 3/20/02(day29) | 3/21/02(day30) |
| PBS 10min | 3/19/02(day28) | 3/20/02(day29) | 3/21/02(day30) |

Prepare OVA solution:

320ml OVA
704ml Alum
544ml PBS

Control

270ml PBS

Stir 30min

220ml Alum No 75161

lot # AE40391

Continued on Page

Read and Understood By

T. P. 3/14/02
Signed Date

veg
Signed

9/25/02
Date

PROJECT Asthma Study

Continued from Page

Schedule of experiment

2/18/02 Monday day1
3/4/02 Monday day14
3/15/02 Friday day25 Treatment group1 anti-C5, dex control antibody 6mice
3/16/02 Saturday day26 Treatment group2 anti-C5, dex control antibody 6 mice
3/18/02 Monday day28 challenge 1%OVA 10 min group1 measure 15min & 4h
3/19/02 Tuesday day29 challenge 1%OVA 10 min & Treat group1 challenge 1%OVA 10 min group2 measure 15min & 4h
3/20/02 Wednesday day30 challenge 1%OVA 10 min group1 measure 15min & 4h Treat group2

3/21/02 Thursday day31 challenge 1%OVA 10 min group2 measure 15min & 4h
3/22/02 Friday day32 Treat group1
3/23/02 Saturday day33 treat group2
3/25/02 Monday challenge 1%OVA 10 min group1 measure 15min & 4h BAL
3/26/02 Tuesday challenge 1%OVA 10 min group2 measure 15min & 4h BAL

| BALE/c | DOB | Weight(g) | Route of administration | Dose of sensitization | Alum | Systemic time | Systemic time |
|--------|----------|-----------|-------------------------|-----------------------|------|---------------|----------------|
| 431 | 11/26/01 | 26.1 | i.p. | 20ug OVA | 2mg | 3/4/02(day1) | 3/18/02(day14) |
| 432 | 11/26/01 | 26.3 | i.p. | 20ug OVA | 2mg | 3/4/02(day1) | 3/18/02(day14) |
| 433 | 11/26/01 | 27.3 | i.p. | 20ug OVA | 2mg | 3/4/02(day1) | 3/18/02(day14) |
| 434 | 11/26/01 | 27.3 | i.p. | 20ug OVA | 2mg | 3/4/02(day1) | 3/18/02(day14) |
| 436 | 11/26/01 | 26.9 | i.p. | 20ug OVA | 2mg | 3/4/02(day1) | 3/18/02(day14) |
| 437 | 11/26/01 | 25.4 | i.p. | 20ug OVA | 2mg | 3/4/02(day1) | 3/18/02(day14) |
| 438 | 11/26/01 | 24.5 | i.p. | 20ug OVA | 2mg | 3/4/02(day1) | 3/18/02(day14) |
| 439 | 11/26/01 | 29.1 | i.p. | 20ug OVA | 2mg | 3/4/02(day1) | 3/18/02(day14) |
| 440 | 11/26/01 | 27.2 | i.p. | 20ug OVA | 2mg | 3/4/02(day1) | 3/18/02(day14) |
| 443 | 11/26/01 | 28.8 | i.p. | PBS | 2mg | 3/4/02(day1) | 3/18/02(day14) |
| 444 | 11/26/01 | 27.6 | i.p. | PBS | 2mg | 3/4/02(day1) | 3/18/02(day14) |
| 445 | 11/26/01 | 25.1 | i.p. | PBS | 2mg | 3/4/02(day1) | 3/18/02(day14) |

Continued on Page

Read and Understood By



3/14/02



9/25/02

Signed

Date

Signed

Date